- In January 2025, the U.S. Food and Drug Administration (FDA) approved Datopotamab Deruxtecan (Datroway), a Trop-2-directed antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo, for patients with unresectable or metastatic, hormone receptor-positive, HER2-negative breast cancer. This therapy offers a targeted approach, delivering cytotoxic agents directly to cancer cells, thereby minimizing damage to healthy tissues
- In January 2025, Eli Lilly announced a definitive agreement to acquire Scorpion Therapeutics' PI3Kα inhibitor program, including the investigational drug STX-478, for up to $2.5 billion. This strategic acquisition aims to enhance Lilly's oncology pipeline, particularly in addressing challenging cancers such as triple-negative breast cancer (TNBC).
- In February 2024, researchers from the University of Adelaide reported that their novel compound, CDDD11-8, effectively inhibited the growth of TNBC tumors in preclinical models without toxic side effects. This orally administered therapy targets the CDK9 protein, which is involved in cancer cell proliferation, and holds promise for future clinical development
- In September 2024, Merck presented data from the Phase 3 KEYNOTE-522 trial demonstrating that Keytruda (pembrolizumab), when combined with chemotherapy before surgery (neoadjuvant) and continued as a single agent after surgery (adjuvant), reduced the risk of death by 34% compared to neoadjuvant chemotherapy alone in patients with high-risk early-stage triple-negative breast cancer (TNBC).
- In December 2024, Lantern Pharma announced that its investigational drug LP-184 received Fast Track designation from the FDA for the treatment of TNBC. LP-184 is a small molecule drug designed to selectively damage DNA in cancer cells with specific biomarkers or mutations, offering a potential targeted therapy for drug-resistant TNBC
